Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α

(2014) David J. Shealy et al.   mAbs

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

(2013) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens

(2013) Sergey S. Seregin et al.   AUTOIMMUNITY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

(2013) M. Talamonti et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriasis as Autoinflammatory Disease

(2013) Joaquin J. Rivas Bejarano et al.   DERMATOLOGIC CLINICS

Which are the antibodies to watch in 2013?

(2013) Janice M. Reichert   mAbs

The critical role of interleukin-23 in spondyloarthropathy

(2013) Jonathan P. Sherlock et al.   MOLECULAR IMMUNOLOGY

Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential

(2013) Alice Gottlieb et al.   Therapeutic Advances in Musculoskeletal Disease

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

(2012) Fabien B Vincent et al.   ANNALS OF THE RHEUMATIC DISEASES

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

(2012) Edward Clark Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

(2012) Paul P Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

(2012) Sandra Garcês et al.   ANNALS OF THE RHEUMATIC DISEASES

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Consensus Guidelines for the Management of Plaque Psoriasis

(2012) Sylvia Hsu   ARCHIVES OF DERMATOLOGY

B effector cells in rheumatoid arthritis and experimental arthritis

(2012) Alison Finnegan et al.   AUTOIMMUNITY

Bi(o)communications among peripheral blood fractions: A focus on NK and NKT cell biology in rheumatoid arthritis

(2012) Ashish Aggarwal et al.   AUTOIMMUNITY

Tight control applied to the biological therapy of rheumatoid arthritis

(2012) Oscar Massimiliano Epis et al.   AUTOIMMUNITY REVIEWS

Different effects of biological drugs in rheumatoid arthritis

(2012) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

Spondyloarthritides

(2012) Xenofon Baraliakos et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Advances in the treatment of inflammatory arthritis

(2012) David S. Pisetsky et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

Comparability and biosimilarity: considerations for the healthcare provider

(2012) Jaymi F. Lee et al.   CURRENT MEDICAL RESEARCH AND OPINION

Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition

(2012) Uta Kiltz et al.   CURRENT OPINION IN RHEUMATOLOGY

Effectiveness and Safety of Local Adalimumab Injection in Patients With Fistulizing Perianal Crohn’s Disease

(2012) Francesco Tonelli et al.   DISEASES OF THE COLON & RECTUM

Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease

(2012) Ali Raza et al.   Expert Review of Clinical Immunology

Natalizumab for moderate to severe Crohnʼs disease in clinical practice: The Mayo Clinic Rochester experience

(2012) S. V. Kane et al.   INFLAMMATORY BOWEL DISEASES

Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohnʼs perianal fistulas

(2012) Phil Tozer et al.   INFLAMMATORY BOWEL DISEASES

Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?

(2012) Denis Mulleman et al.   JOINT BONE SPINE

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update

(2012) Alexander Nast et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Critical role of the interleukin-23//T-helper 17 cell axis in the pathogenesis of psoriasis

(2012) Kimiko NAKAJIMA   JOURNAL OF DERMATOLOGY

The concept of psoriasis as a systemic inflammation: implications for disease management

(2012) K. Reich   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ulcerative colitis

(2012) Ingrid Ordás et al.   LANCET

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Immune aspects of the pathogenesis of inflammatory bowel disease

(2012) Tadakazu Hisamatsu et al.   PHARMACOLOGY & THERAPEUTICS

Early Spondyloarthritis

(2012) Denis Poddubnyy et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

The Genetics of Ankylosing Spondylitis and Axial Spondyloarthritis

(2012) Philip C. Robinson et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review

(2012) R. J. Moots et al.   RHEUMATOLOGY

Artrite psoriásica: entidade clínica distinta da psoríase?

(2012) Danilo Garcia Ruiz et al.   Revista Brasileira De Reumatologia

Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis

(2012) Salih Ozgocmen et al.   Current Rheumatology Reports

Inflammatory Rheumatic Disorders and Bone

(2012) Irene E. M. Bultink et al.   Current Rheumatology Reports

Biologic Therapies for Spondyloarthritis: What Is New?

(2012) Xenofon Baraliakos et al.   Current Rheumatology Reports

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety

(2011) Gert Van Assche et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

(2011) D. van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

(2011) Zoe Ash et al.   ANNALS OF THE RHEUMATIC DISEASES

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

(2011) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

What’s new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010

(2011) A. C. Foulkes et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Etanercept: efficacy and safety for approved indications

(2011) Todd A Kerensky et al.   Expert Opinion On Drug Safety

Efalizumab

(2011) Marina Talamonti et al.   Expert Opinion On Drug Safety

Epidemiology and Natural History of Inflammatory Bowel Diseases

(2011) Jacques Cosnes et al.   GASTROENTEROLOGY

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

New therapies for inflammatory bowel disease: from the bench to the bedside

(2011) Silvio Danese   GUT

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1

(2011) N Vande Casteele et al.   GUT

Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation

(2011) G. Barosi et al.   HAEMATOLOGICA

Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease

(2011) Benjamin Pariente et al.   INFLAMMATORY BOWEL DISEASES

Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: Ten-year results from the IBSEN study

(2011) Marte Lie Høivik et al.   Journal of Crohns & Colitis

Genetics and pathogenesis of inflammatory bowel disease

(2011) Bernard Khor et al.   NATURE

Spondyloarthritides: evolving therapies

(2011) Andrew Barr et al.   ARTHRITIS RESEARCH & THERAPY

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept

(2010) A. Jamnitski et al.   ANNALS OF THE RHEUMATIC DISEASES

The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

(2010) M. Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Rheumatoid arthritis therapy: Advances from bench to bedside

(2010) Soo-In Choi et al.   AUTOIMMUNITY

Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis

(2010) Kim Papp   CURRENT MEDICAL RESEARCH AND OPINION

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆

(2010) Ambrogio Orlando et al.   DIGESTIVE AND LIVER DISEASE

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

(2010) Batya B. Davidovici et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality control and analytical techniques for biopharmaceuticals

(2010) C Jane Robinson et al.   Bioanalysis

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

(2009) A Finckh et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Manufacturing of Biodrugs

(2009) Niharika Sahoo et al.   BIODRUGS

Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study

(2009) A.E. Pink et al.   BRITISH JOURNAL OF DERMATOLOGY

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

(2009) C H Seow et al.   GUT

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

(2009) Yaowei Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics

(2009) E Christophers et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice

(2009) D. Elewaut et al.   RHEUMATOLOGY

Follow-on protein products: scientific issues, developments and challenges

(2009) Anurag S. Rathore   TRENDS IN BIOTECHNOLOGY

New insights into the pathogenesis and genetics of psoriatic arthritis

(2009) Kristine E Nograles et al.   Nature clinical practice. Rheumatology

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Specific Microbiota Direct the Differentiation of IL-17-Producing T-Helper Cells in the Mucosa of the Small Intestine

(2008) Ivaylo I. Ivanov et al.   Cell Host & Microbe

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council

(2008) A. Covic et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS